283. 後天性赤芽球癆
[臨床試験数:17,薬物数:36(DrugBank:19),標的遺伝子数:16,標的パスウェイ数:91

Searched query = "Acquired pure red cell aplasia", "Pure red cell aplasia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04423367
(ClinicalTrials.gov)
September 13, 20205/6/2020Bortezomib Plus Dexamethasone for Acquired Pure Red Cell Aplasia Failure or Relapse After First-line TreatmentSafety and Efficacy of Bortezomib Plus Dexamethasone for Acquired Pure Red Cell Aplasia Failure or Relapse After First-line Treatment: A Prospective Phase II TrialAcquired Pure Red Cell AplasiaDrug: bortezomib/dexamethasoneInstitute of Hematology & Blood Diseases HospitalNULLRecruiting18 Years70 YearsAll17Phase 2China